Kimberly Badal
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kimberly Badal has a total of 82 co-authors. Here are the top co-authors by number of shared publications:
Rajini Haraksingh
University of the West Indies
3 shared publications- Adetunji T. Toriola
Division of Public Health Sciences, Department of Surgery, Washington University School of Medicine, St Louis, Missouri
2 shared publications Akash Maniam
Caribbean Cancer Research Institute, El Socorro, Trinidad and Tobago
2 shared publicationsJerome E. Foster
University of the West Indies
2 shared publicationsLaura J. Esserman
Department of Surgery, University of California San Francisco, San Francisco, USA
2 shared publicationsRehanna Ali
Department of Life Sciences, Faculty of Science and Technology, The University of the West Indies, St. Augustine, Trinidad and Tobago
2 shared publications
Latest Publications
- Open Access
- 3 July 2025
- Published by Springer Nature in BMC Global and Public Health
- Vol. 3 (1) , 1-3
Translating risk-based breast cancer screening to limited-resource settings
- 3 July 2025
- Published by Springer Nature in BMC Global and Public Health
- Vol. 3 (1) , 1-3
Open AccessTranslating risk-based breast cancer screening to limited-resource settings
- Open Access
- 6 June 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (23) , eadt5708
Predicting therapeutic clinical trial enrollment for adult patients with low- and high-grade glioma using supervised machine learning
Therapeutic clinical trial enrollment does not match glioma incidence across demographics. Traditional statistical methods have identified independent predictors of trial enrollment; however, our understanding of the interactions between these factors remains limited. To test the interactive effects of demographic, socioeconomic, and oncologic variables on trial enrollment, we designed boosted neural networks (BNNs) for all glioma patients ( n = 1042), women ( n = 445, 42.7%), and minorities ( n = 151, 14.5%) and externally validated these models [whole cohort, n = 230; women, n = 89 (38.7%); minority, n = 66 (28.7%)]. For the whole-cohort BNN, the most influential variables on enrollment were oncologic variables, including KPS [total effect (TE), 0.327], chemotherapy (TE, 0.326), tumor location (TE, 0.322), and seizures (TE, 0.239). The women-only BNN exhibited a similar trend. Conversely, for the minority-only BNN, socioeconomic variables [insurance status (TE, 0.213), occupation classification (TE, 0.204), and employment status (TE, 0.150)] were most influential. These results may help prioritize patient-specific initiatives to increase accrual.
- 6 June 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (23) , eadt5708
Open AccessPredicting therapeutic clinical trial enrollment for adult patients with low- and high-grade glioma using supervised machine learning
Therapeutic clinical trial enrollment does not match glioma incidence across demographics. Traditional statistical methods have identified independent predictors of trial enrollment; however, our understanding of the interactions between these factors remains limited. To test the interactive effects of demographic, socioeconomic, and oncologic variables on trial enrollment, we designed boosted neural networks (BNNs) for all glioma patients ( n = 1042), women ( n = 445, 42.7%), and minorities ( n = 151, 14.5%) and externally validated these models [whole cohort, n = 230; women, n = 89 (38.7%); minority, n = 66 (28.7%)]. For the whole-cohort BNN, the most influential variables on enrollment were oncologic variables, including KPS [total effect (TE), 0.327], chemotherapy (TE, 0.326), tumor location (TE, 0.322), and seizures (TE, 0.239). The women-only BNN exhibited a similar trend. Conversely, for the minority-only BNN, socioeconomic variables [insurance status (TE, 0.213), occupation classification (TE, 0.204), and employment status (TE, 0.150)] were most influential. These results may help prioritize patient-specific initiatives to increase accrual.
- 1 June 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 11 (11) , e2400535
Results of Five Years of a Cancer Patient Navigation Training Program for Limited-Resource Settings in the Caribbean and Africa
PURPOSE: Cancer patient navigation (CPN) training programs in the United States do not address the unique challenges of limited-resource settings. This study evaluates knowledge acquisition, utilization, and participant feedback from the Caribbean Cancer Research Institute's (CCRI) CPN training program, which trained participants from the Caribbean, Botswana, and Kenya between 2018 and 2023. METHODS: The CCRI conducted in-person CPN training in 2018 and 2019, paused in 2020 because of the COVID-19 pandemic, and transitioned to a virtual format in 2021. The program, delivered annually, expanded its curriculum and included participants from Kenya and Botswana. Knowledge acquisition was assessed through a 60-question pretest and post-test, and a 23-question program evaluation survey measured participant satisfaction. A follow-up eight-question survey assessed knowledge utilization. Summary statistics were used to describe participant demographics and survey responses, whereas paired t-tests were used to compare pretest and post-test scores. RESULTS: The virtual, self-paced CCRI CPN Training Program covered 11 topics over 12 hours. Between 2018 and 2023, 55 participants enrolled: 80% (n = 44) passed, 18% (n = 10) failed, and 2% (n = 1) did not complete the course. Most participants (95%, n = 52) were from the Caribbean, with 80% (n = 44) from Trinidad and Tobago. Three participants were from Botswana and Kenya. The majority were female (98%, n = 54) and nurses (36%, n = 20), and did not have a personal history of cancer (89%, n = 49). Significant knowledge gains ( P < .001) were observed across all years except 2023. Participants expressed high satisfaction and suggested improvements. Twenty-two percent (n = 6 of 27) secured employment as patient navigators in oncology settings. CONCLUSION: The CCRI CPN training program trained participants across the Caribbean and showed preliminary acceptability in Kenya and Botswana. Strengths include its low-cost, virtual, self-paced format, adaptability to limited-resource settings, and region-specific content. Future efforts will focus on updating training materials and expanding recruitment.
- 1 June 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 11 (11) , e2400535
Results of Five Years of a Cancer Patient Navigation Training Program for Limited-Resource Settings in the Caribbean and Africa
PURPOSE: Cancer patient navigation (CPN) training programs in the United States do not address the unique challenges of limited-resource settings. This study evaluates knowledge acquisition, utilization, and participant feedback from the Caribbean Cancer Research Institute's (CCRI) CPN training program, which trained participants from the Caribbean, Botswana, and Kenya between 2018 and 2023. METHODS: The CCRI conducted in-person CPN training in 2018 and 2019, paused in 2020 because of the COVID-19 pandemic, and transitioned to a virtual format in 2021. The program, delivered annually, expanded its curriculum and included participants from Kenya and Botswana. Knowledge acquisition was assessed through a 60-question pretest and post-test, and a 23-question program evaluation survey measured participant satisfaction. A follow-up eight-question survey assessed knowledge utilization. Summary statistics were used to describe participant demographics and survey responses, whereas paired t-tests were used to compare pretest and post-test scores. RESULTS: The virtual, self-paced CCRI CPN Training Program covered 11 topics over 12 hours. Between 2018 and 2023, 55 participants enrolled: 80% (n = 44) passed, 18% (n = 10) failed, and 2% (n = 1) did not complete the course. Most participants (95%, n = 52) were from the Caribbean, with 80% (n = 44) from Trinidad and Tobago. Three participants were from Botswana and Kenya. The majority were female (98%, n = 54) and nurses (36%, n = 20), and did not have a personal history of cancer (89%, n = 49). Significant knowledge gains ( P < .001) were observed across all years except 2023. Participants expressed high satisfaction and suggested improvements. Twenty-two percent (n = 6 of 27) secured employment as patient navigators in oncology settings. CONCLUSION: The CCRI CPN training program trained participants across the Caribbean and showed preliminary acceptability in Kenya and Botswana. Strengths include its low-cost, virtual, self-paced format, adaptability to limited-resource settings, and region-specific content. Future efforts will focus on updating training materials and expanding recruitment.
- Open Access
National yearly cost of breast cancer screening in the USA and projected cost of advocated guidelines: a simulation study with life table modelling
Objective The aim of this study was to estimate the total national direct cost of breast cancer screening from 2019 to 2022 and project the total national cost and average lifetime cost of screening per woman for three current guidelines. Design We estimated the national cost of screening from 2019 to 2022, and per cancer detected in 2022, using real-world data on the number of mammograms performed per year. We also projected the national cost of screening using life table modelling for three guidelines: 2021/2023 American College of Radiology (ACR), 2023 American Cancer Society (ACS) and 2024 United States Preventative Services Task Force (USPSTF). The average lifetime cost to screen one woman until age 74 years with each guideline was also estimated. The Optum Labs Data Warehouse was used to estimate commercial and Medicare costs and recall rates. Sensitivity analyses were used to estimate uncertainty and determine which inputs had the largest impact on total national costs. Setting This study was conducted for the USA. Participants Women eligible for breast cancer screening. Interventions Digital mammograms (2D) or digital breast tomosynthesis (3D) and/or MRI. Primary outcome measure Total national cost of screening calculated as the sum of screening and recall costs. Average lifetime cost of screening per woman until 74 years. Results Nationally, screening cost approximately US$11 billion (B) per year from 2019 to 2022 with approximately 37% of eligible women screened each year. In 2022, screening cost US$55 471 per 3D-detected and US$44 000 per 2D-detected invasive or ductal carcinoma in situ case. Using target yearly participation rates of 54%–78% by age of women, the projected cost of screening was US$30B for ACR, US$18B for ACS and US$8B for USPSTF guidelines. The average lifetime cost to screen an average-risk woman was: US$13 416 for ACR, US$7946 for ACS and US$6931 for USPSTF. Participation rates, the proportion of women with a lifetime risk>20% and commercial MRI and 3D costs had the largest impact on total costs. Conclusion The cost of screening varies significantly by guideline (US$8B–US$30B) and was most influenced by participation rates, high-risk population proportions and technology costs. Future work can investigate whether risk-based screening strategies being tested in ongoing clinical trials can reduce national screening costs while improving outcomes.Cite Now
Open AccessNational yearly cost of breast cancer screening in the USA and projected cost of advocated guidelines: a simulation study with life table modelling
Objective The aim of this study was to estimate the total national direct cost of breast cancer screening from 2019 to 2022 and project the total national cost and average lifetime cost of screening per woman for three current guidelines. Design We estimated the national cost of screening from 2019 to 2022, and per cancer detected in 2022, using real-world data on the number of mammograms performed per year. We also projected the national cost of screening using life table modelling for three guidelines: 2021/2023 American College of Radiology (ACR), 2023 American Cancer Society (ACS) and 2024 United States Preventative Services Task Force (USPSTF). The average lifetime cost to screen one woman until age 74 years with each guideline was also estimated. The Optum Labs Data Warehouse was used to estimate commercial and Medicare costs and recall rates. Sensitivity analyses were used to estimate uncertainty and determine which inputs had the largest impact on total national costs. Setting This study was conducted for the USA. Participants Women eligible for breast cancer screening. Interventions Digital mammograms (2D) or digital breast tomosynthesis (3D) and/or MRI. Primary outcome measure Total national cost of screening calculated as the sum of screening and recall costs. Average lifetime cost of screening per woman until 74 years. Results Nationally, screening cost approximately US$11 billion (B) per year from 2019 to 2022 with approximately 37% of eligible women screened each year. In 2022, screening cost US$55 471 per 3D-detected and US$44 000 per 2D-detected invasive or ductal carcinoma in situ case. Using target yearly participation rates of 54%–78% by age of women, the projected cost of screening was US$30B for ACR, US$18B for ACS and US$8B for USPSTF guidelines. The average lifetime cost to screen an average-risk woman was: US$13 416 for ACR, US$7946 for ACS and US$6931 for USPSTF. Participation rates, the proportion of women with a lifetime risk>20% and commercial MRI and 3D costs had the largest impact on total costs. Conclusion The cost of screening varies significantly by guideline (US$8B–US$30B) and was most influenced by participation rates, high-risk population proportions and technology costs. Future work can investigate whether risk-based screening strategies being tested in ongoing clinical trials can reduce national screening costs while improving outcomes.Cite Now
- Open Access
- 1 April 2023
- Published by Springer Nature in Communications Medicine
- Vol. 3 (1) , 1-6
Guiding principles for the responsible development of artificial intelligence tools for healthcare
Several principles have been proposed to improve use of artificial intelligence (AI) in healthcare, but the need for AI to improve longstanding healthcare challenges has not been sufficiently emphasized. We propose that AI should be designed to alleviate health disparities, report clinically meaningful outcomes, reduce overdiagnosis and overtreatment, have high healthcare value, consider biographical drivers of health, be easily tailored to the local population, promote a learning healthcare system, and facilitate shared decision-making. These principles are illustrated by examples from breast cancer research and we provide questions that can be used by AI developers when applying each principle to their work.
- 1 April 2023
- Published by Springer Nature in Communications Medicine
- Vol. 3 (1) , 1-6
Open AccessGuiding principles for the responsible development of artificial intelligence tools for healthcare
Several principles have been proposed to improve use of artificial intelligence (AI) in healthcare, but the need for AI to improve longstanding healthcare challenges has not been sufficiently emphasized. We propose that AI should be designed to alleviate health disparities, report clinically meaningful outcomes, reduce overdiagnosis and overtreatment, have high healthcare value, consider biographical drivers of health, be easily tailored to the local population, promote a learning healthcare system, and facilitate shared decision-making. These principles are illustrated by examples from breast cancer research and we provide questions that can be used by AI developers when applying each principle to their work.
- Open Access
- 1 September 2022
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 132 (17)
Falling down the biological rabbit hole: Epstein-Barr virus, biography, and multiple sclerosis
- 1 September 2022
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 132 (17)
Open AccessFalling down the biological rabbit hole: Epstein-Barr virus, biography, and multiple sclerosis
- Open Access
- 10 February 2022
- Published by Springer Nature in Research Square
Genomic Machine Learning Model Predicts Radiation Therapy Benefit in Early-Stage Breast Cancer Patients with High Accuracy
BackgroundRadiation therapy (RT) is frequently recommended for post-surgery treatment of early-stage breast cancer (BC) patients, though not all benefit. Clinical factors currently guide RT treatment decisions. At present, models to predict RT-benefit predominantly use statistical methods with modest performance. In this paper we present a high-accuracy genomic Machine Learning (ML) model to predict RT-benefit in early-stage BC patients. We also present a novel method for selecting genomic features for training ML algorithms. MethodsGene expression data from 463 early-stage BC patients treated with surgery and RT from the METABRIC cohort were obtained. Wilcoxon Rank Sum (Wilcoxon RS) test and Cox Proportional Hazards (Cox PH) were used to reduce the number of genes used to train eight ML algorithms. ML algorithms were trained on 80% of data using 10-fold cross validation and tested on 20% of data to assess performance in predicting relapse status. Results Genome-wide gene expression data was reduced by 96% using Wilcoxon RS and Cox PH to a 1,596 gene set and a 977 gene set. These gene sets were used to train eight ML algorithms resulting in models that ranged in performance accuracies from 54.01% to 95.6%. Highest accuracies were obtained using Support Vector Machine (SVM977–93.41%, SVM1596–95.6%) and Neural Networks algorithms (NN977 – 92.31%, NN1596 – 93.41%). In RT-untreated patients, accuracies of all models were 30% to 40% lower compared to RT-treated patients. SVM977 had the highest sensitivity of 91.09%. Members of the 977 set were enriched with genes involved in cell cycle and differentiation as well as genes associated with radiosensitivity and radioresistance.Conclusion This study presents a novel genomic feature selection approach that used Wilcoxon RS followed by Cox PH to reduce the number of genes from genome-wide gene expression data used for training ML algorithms by 96%. This approach led to an SVM model that used the expression values of 977 genes to predict RT-benefit in early-stage BC patients with 93.41% accuracy. This work demonstrates that ML models can be clinically useful for predicting cancer patient outcomes.
- 10 February 2022
- Published by Springer Nature in Research Square
Open AccessGenomic Machine Learning Model Predicts Radiation Therapy Benefit in Early-Stage Breast Cancer Patients with High Accuracy
BackgroundRadiation therapy (RT) is frequently recommended for post-surgery treatment of early-stage breast cancer (BC) patients, though not all benefit. Clinical factors currently guide RT treatment decisions. At present, models to predict RT-benefit predominantly use statistical methods with modest performance. In this paper we present a high-accuracy genomic Machine Learning (ML) model to predict RT-benefit in early-stage BC patients. We also present a novel method for selecting genomic features for training ML algorithms. MethodsGene expression data from 463 early-stage BC patients treated with surgery and RT from the METABRIC cohort were obtained. Wilcoxon Rank Sum (Wilcoxon RS) test and Cox Proportional Hazards (Cox PH) were used to reduce the number of genes used to train eight ML algorithms. ML algorithms were trained on 80% of data using 10-fold cross validation and tested on 20% of data to assess performance in predicting relapse status. Results Genome-wide gene expression data was reduced by 96% using Wilcoxon RS and Cox PH to a 1,596 gene set and a 977 gene set. These gene sets were used to train eight ML algorithms resulting in models that ranged in performance accuracies from 54.01% to 95.6%. Highest accuracies were obtained using Support Vector Machine (SVM977–93.41%, SVM1596–95.6%) and Neural Networks algorithms (NN977 – 92.31%, NN1596 – 93.41%). In RT-untreated patients, accuracies of all models were 30% to 40% lower compared to RT-treated patients. SVM977 had the highest sensitivity of 91.09%. Members of the 977 set were enriched with genes involved in cell cycle and differentiation as well as genes associated with radiosensitivity and radioresistance.Conclusion This study presents a novel genomic feature selection approach that used Wilcoxon RS followed by Cox PH to reduce the number of genes from genome-wide gene expression data used for training ML algorithms by 96%. This approach led to an SVM model that used the expression values of 977 genes to predict RT-benefit in early-stage BC patients with 93.41% accuracy. This work demonstrates that ML models can be clinically useful for predicting cancer patient outcomes.
- Open Access
- 1 July 2021
- Published by Taylor & Francis in Cancer Management and Research
- Vol. ume 13, 5433-5442
The Repository for Caribbean Cancer Publications (ReCCaP): Database Development and Publication Trends 2004–2019
Objective: In the Caribbean region, research has been limited, making it challenging to find. In order for the region to optimally access and utilize present research and identify gaps, we developed the Repository for Caribbean Cancer Publications (ReCCaP) to home publications on cancer in the Caribbean population and diaspora and report on publication trends. Methods: A systematic PubMed literature search for the period 2004– 2019 (15 years) was developed using keywords related to “cancer” and “Caribbean.” Three independent investigators verified included publications. The final database was formatted and hosted in an online database management software. Publication trends over time, by country, cancer type, and income classification were investigated. Results: Of the 4935 publications found, 1194 papers met the inclusion criteria with 803 publications (67.25%) being on the Caribbean population, 139 publications (11.64%) including multiple Caribbean countries and 252 publications (21.11%) on the diaspora. Between 2004 and 2019, there was an overall 0.20 increase in publications regionally. Overall, most publications were on breast (n = 168, 14.07%), prostate (n = 156, 13.07%), cervical (n = 152, 12.73%), colorectal (n = 80, 6.70%), and lung cancer (n = 36, 3.02%). The highest number of papers were published by Puerto Rico (22.80 pubs/year), Cuba (8.27 pubs/year), Jamaica (6.27 pubs/year), Trinidad and Tobago (3.53 pubs/year), and Martinique (2.27 pubs/year). The high-income countries (n=10) collectively lead in publications over the 15-year period. Conclusion: ReCCaP provides an easily searchable database highlighting published work and gaps in knowledge on cancer in the Caribbean and diaspora.
- 1 July 2021
- Published by Taylor & Francis in Cancer Management and Research
- Vol. ume 13, 5433-5442
Open AccessThe Repository for Caribbean Cancer Publications (ReCCaP): Database Development and Publication Trends 2004–2019
Objective: In the Caribbean region, research has been limited, making it challenging to find. In order for the region to optimally access and utilize present research and identify gaps, we developed the Repository for Caribbean Cancer Publications (ReCCaP) to home publications on cancer in the Caribbean population and diaspora and report on publication trends. Methods: A systematic PubMed literature search for the period 2004– 2019 (15 years) was developed using keywords related to “cancer” and “Caribbean.” Three independent investigators verified included publications. The final database was formatted and hosted in an online database management software. Publication trends over time, by country, cancer type, and income classification were investigated. Results: Of the 4935 publications found, 1194 papers met the inclusion criteria with 803 publications (67.25%) being on the Caribbean population, 139 publications (11.64%) including multiple Caribbean countries and 252 publications (21.11%) on the diaspora. Between 2004 and 2019, there was an overall 0.20 increase in publications regionally. Overall, most publications were on breast (n = 168, 14.07%), prostate (n = 156, 13.07%), cervical (n = 152, 12.73%), colorectal (n = 80, 6.70%), and lung cancer (n = 36, 3.02%). The highest number of papers were published by Puerto Rico (22.80 pubs/year), Cuba (8.27 pubs/year), Jamaica (6.27 pubs/year), Trinidad and Tobago (3.53 pubs/year), and Martinique (2.27 pubs/year). The high-income countries (n=10) collectively lead in publications over the 15-year period. Conclusion: ReCCaP provides an easily searchable database highlighting published work and gaps in knowledge on cancer in the Caribbean and diaspora.
- 9 April 2021
- Published by Springer Nature in Cancer Causes & Control
- Vol. 32 (7) , 763-772
Factors associated with breast cancer recurrence and survival at Sangre Grande Hospital, Trinidad
Purpose The aim of this study is to determine the demographic, pathological, and treatment-related factors that predict recurrence and survival in a Trinidadian cohort of breast cancer patients. Methods The inclusion criteria for this study were female, over 18 years, and with a primary breast cancer diagnosis confirmed by a biopsy report occurring between 2010 and 2015 at Sangre Grande Hospital, Trinidad. Univariate associations with 5-year recurrence-free survival and 5-year overall survival were calculated using the Kaplan–Meier method for categorical variables and Cox Proportional Hazards for continuous variables. A multivariate model for prediction of recurrence and survival was determined using Cox regression. Results For the period 2010–2015, 202 records were abstracted. Five-year overall survival and recurrence-free survival rates were found to be 74.3% and 56.4%, respectively. Median times from first suspicious finding to date of biopsy report, date of surgery, and date of chemotherapy were 63 days, 125 days, and 189 days, respectively. In the univariate analysis, age (p = 0.038), stage (p < 0.001), recurrence (p = 0.035), surgery (p = 0.016), ER (p < 0.001) status, PR status (p < 0.001), and subtype (p < 0.001) were significantly associated with survival. Additionally, stage (p = 0.004), N score (p = 0.002), ER (p = 0.028) status, PR (p = 0.018) status, and subtype (p = 0.025) were significantly associated with recurrence. In the Cox multivariate model, Stage 4 was a significant predictor of survival (HR 6.77, 95% CI [0.09–2.49], p = 0.047) and N3 score was a significant predictor of recurrence (HR 4.47, 95% CI [1.29–15.54], p = 0.018). Conclusion This study reports a 5-year breast cancer survival rate of 74.3%, and a recurrence-free survival rate of 56.4% in Trinidad for the period 2010–2015.
- 9 April 2021
- Published by Springer Nature in Cancer Causes & Control
- Vol. 32 (7) , 763-772
Factors associated with breast cancer recurrence and survival at Sangre Grande Hospital, Trinidad
Purpose The aim of this study is to determine the demographic, pathological, and treatment-related factors that predict recurrence and survival in a Trinidadian cohort of breast cancer patients. Methods The inclusion criteria for this study were female, over 18 years, and with a primary breast cancer diagnosis confirmed by a biopsy report occurring between 2010 and 2015 at Sangre Grande Hospital, Trinidad. Univariate associations with 5-year recurrence-free survival and 5-year overall survival were calculated using the Kaplan–Meier method for categorical variables and Cox Proportional Hazards for continuous variables. A multivariate model for prediction of recurrence and survival was determined using Cox regression. Results For the period 2010–2015, 202 records were abstracted. Five-year overall survival and recurrence-free survival rates were found to be 74.3% and 56.4%, respectively. Median times from first suspicious finding to date of biopsy report, date of surgery, and date of chemotherapy were 63 days, 125 days, and 189 days, respectively. In the univariate analysis, age (p = 0.038), stage (p < 0.001), recurrence (p = 0.035), surgery (p = 0.016), ER (p < 0.001) status, PR status (p < 0.001), and subtype (p < 0.001) were significantly associated with survival. Additionally, stage (p = 0.004), N score (p = 0.002), ER (p = 0.028) status, PR (p = 0.018) status, and subtype (p = 0.025) were significantly associated with recurrence. In the Cox multivariate model, Stage 4 was a significant predictor of survival (HR 6.77, 95% CI [0.09–2.49], p = 0.047) and N3 score was a significant predictor of recurrence (HR 4.47, 95% CI [1.29–15.54], p = 0.018). Conclusion This study reports a 5-year breast cancer survival rate of 74.3%, and a recurrence-free survival rate of 56.4% in Trinidad for the period 2010–2015.
- Open Access
- 4 July 2018
- Published by Springer Nature in BMC Cancer
- Vol. 18 (1) , 712
Cancer incidence and mortality rates and trends in Trinidad and Tobago
Cancer is the second leading cause of death in the Caribbean, including the islands of Trinidad and Tobago (TT). The population of TT consists of over 1.3 million people with diverse ancestral and sociocultural backgrounds, both of which may influence cancer incidence and mortality. The objective of this study was to examine incidence and mortality patterns and trends in TT. Cancer surveillance data on 29,512 incident cancer cases reported to the Dr. Elizabeth Quamina Cancer Registry (population-based cancer registry of TT) between 1995 and 2009 were analyzed. Age-standardized rates, overall and by sex, ancestry, and geography, were reported. The highest incidence and mortality rates were observed for cancers related to reproductive organs in women, namely, breast, cervical, and uterine cancers, and prostate, lung and colorectal cancers among men. Average incidence rates were highest in areas covered by the Tobago Regional Health Authority (TRHA) (188 per 100,000), while average mortality rates were highest in areas covered by the North West Regional Health Authority (108 per 100,000). Nationals of African ancestry exhibited the highest rates of cancer incidence (243 per 100,000) and mortality (156 per 100,000) compared to their counterparts who were of East Indian (incidence, 125 per 100,000; mortality, 66 per 100,000) or mixed ancestry (incidence, 119 per 100,000; mortality, 66 per 100,000). Our findings highlight the need for national investment to improve the understanding of the epidemiology of cancer in Trinidad and Tobago, and to ultimately guide much needed cancer prevention and control initiatives in the near future.
- 4 July 2018
- Published by Springer Nature in BMC Cancer
- Vol. 18 (1) , 712
Open AccessCancer incidence and mortality rates and trends in Trinidad and Tobago
Cancer is the second leading cause of death in the Caribbean, including the islands of Trinidad and Tobago (TT). The population of TT consists of over 1.3 million people with diverse ancestral and sociocultural backgrounds, both of which may influence cancer incidence and mortality. The objective of this study was to examine incidence and mortality patterns and trends in TT. Cancer surveillance data on 29,512 incident cancer cases reported to the Dr. Elizabeth Quamina Cancer Registry (population-based cancer registry of TT) between 1995 and 2009 were analyzed. Age-standardized rates, overall and by sex, ancestry, and geography, were reported. The highest incidence and mortality rates were observed for cancers related to reproductive organs in women, namely, breast, cervical, and uterine cancers, and prostate, lung and colorectal cancers among men. Average incidence rates were highest in areas covered by the Tobago Regional Health Authority (TRHA) (188 per 100,000), while average mortality rates were highest in areas covered by the North West Regional Health Authority (108 per 100,000). Nationals of African ancestry exhibited the highest rates of cancer incidence (243 per 100,000) and mortality (156 per 100,000) compared to their counterparts who were of East Indian (incidence, 125 per 100,000; mortality, 66 per 100,000) or mixed ancestry (incidence, 119 per 100,000; mortality, 66 per 100,000). Our findings highlight the need for national investment to improve the understanding of the epidemiology of cancer in Trinidad and Tobago, and to ultimately guide much needed cancer prevention and control initiatives in the near future.